Chemo/imaging combo aids prostate cancer treatment
Researchers may have found a way to combine imaging with chemotherapy in a single agent for the treatment of prostate cancer, according to data presented this week at the 100th annual meeting of the American Association for Cancer Research (AACR) in Denver. "It's like a smart bomb, to use a military analogy," said John P. Sedelaar, PhD, MD, a postdoctoral research fellow at Johns Hopkins University in Baltimore. "By retooling chemotherapy agents, we may be able to get more accurate treatment monitoring and follow-up."
Sedelaar said that current clinical practice uses multimodality MRI to examine the urological system for diagnosing prostate cancer. This tool, however, is mostly thought of as a prostate imaging method, rather than a prostate cancer imaging method.
"An increasing number of patients have minimal prostate cancer, and opt for either very focused treatment or the watchful waiting approach," Sedelaar said. "In this environment, the need for an accurate imaging tool is paramount."
Sedelaar and colleagues designed two imaging drugs: a PSMA and a PSA-activated pro-drug. The agents are therapeutic drugs that are modified by adding a tyrosine ring for imaging.
Following administration into laboratory mice, the researchers noted a measureable reduction in prostate cancer cells.
Experiments also showed that the imaging pro-drugs were cleaved and activated by PSMA or PSA, suggesting their viability as a prostate cancer imaging modality.
"Unfortunately, next to clear tumor uptake there was also uptake into liver and kidney organs. Further experiments will have to address that problem," said Sedelaar.
Sedelaar said that current clinical practice uses multimodality MRI to examine the urological system for diagnosing prostate cancer. This tool, however, is mostly thought of as a prostate imaging method, rather than a prostate cancer imaging method.
"An increasing number of patients have minimal prostate cancer, and opt for either very focused treatment or the watchful waiting approach," Sedelaar said. "In this environment, the need for an accurate imaging tool is paramount."
Sedelaar and colleagues designed two imaging drugs: a PSMA and a PSA-activated pro-drug. The agents are therapeutic drugs that are modified by adding a tyrosine ring for imaging.
Following administration into laboratory mice, the researchers noted a measureable reduction in prostate cancer cells.
Experiments also showed that the imaging pro-drugs were cleaved and activated by PSMA or PSA, suggesting their viability as a prostate cancer imaging modality.
"Unfortunately, next to clear tumor uptake there was also uptake into liver and kidney organs. Further experiments will have to address that problem," said Sedelaar.